PacBio reports Q4 preliminary revenue $27.3M (-24% YoY); received orders for 76 Revio systems

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2022-FY EPS reported -$1.40 revenue$128,304,000

Q4 2022 preliminary revenue $27.3M, down 24% from $36.0M in Q4 2021.
Full-year 2022 preliminary revenue $128.2M, down 2% from 2021.
Received orders for 76 Revio systems in Q4 2022, record product announcement.
Cash, cash equivalents, and investments ~$772.3M as of Dec 31, 2022.
Onso beta feedback positive; orders expected Q1 2023, shipments by end of Q2 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fourth quarter ended December 31, 2022 results: revenue approximately $27.3 million.

Period: fourth quarter ended December 31, 2022
Revenue: approximately $27.3 million
Result: preliminary results

Exact text from the filing

PacBio reported unaudited preliminary revenue of approximately $27.3 million for its fourth quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001299130-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.